3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Carcinoma, Non-Small-Cell Lung
7
Colorectal Neoplasms
6
Biliary Tract Neoplasms
5
Sarcoma
3
Rectal Neoplasms
3
Colonic Neoplasms
3
Advanced or Metastatic Solid Tumors
3
Solid Tumors
2
Nasopharyngeal Carcinoma
2
Gastrointestinal Stromal Tumors
2
Carcinoma, Hepatocellular
2
Uterine Cervical Neoplasms
1
Thymoma
1
Stomach Neoplasms
1
Squamous Non-small Cell Lung Cancer
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Rare Tumour
1
Prostatic Neoplasms
1
Piebaldism
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neoplasms, Multiple Primary
1
Neoplasm Metastasis
1
NSCLC
1
Meningeal Carcinomatosis
1
Lung Neoplasms
1
Histiocytoma, Malignant Fibrous
1
HER2-positive Breast Cancer
1
Gastrointestinal Neoplasms
1
Interventions
Doxorubicin
9
Imatinib Mesylate
6
pazopanib
4
Ifosfamide
4
Radiotherapy
3
Gemcitabine
3
Docetaxel
3
pembrolizumab
2
Radiation
2
Neoadjuvant Therapy
2
Biopsy
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
selinexor
1
saracatinib
1
sapanisertib
1
ribociclib
1
peposertib
1
liposomal doxorubicin
1
indolepropanol phosphate
1
envafolimab
1
cixutumumab
1
brigimadlin
1
avelumab
1
X-Rays
1
Watchful Waiting
1
TTI-621
1
Sunitinib
1
Specimen Handling
1
Razoxane
1
Radiotherapy, Intensity-Modulated
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Dermatofibrosarcoma
×
envafolimab
×
Clear all
NCT04480502
2024-05-17
ENVASARC
Tracon Pharmaceuticals Inc.
Phase 2
Active not recruiting
207 enrolled